216 related articles for article (PubMed ID: 28292938)
1. Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.
Langdon CG; Platt JT; Means RE; Iyidogan P; Mamillapalli R; Klein M; Held MA; Lee JW; Koo JS; Hatzis C; Hochster HS; Stern DF
Mol Cancer Ther; 2017 Jun; 16(6):1041-1053. PubMed ID: 28292938
[TBL] [Abstract][Full Text] [Related]
2. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
3. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
4. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
7. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
8. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
[TBL] [Abstract][Full Text] [Related]
9. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
10. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
[TBL] [Abstract][Full Text] [Related]
11. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
[TBL] [Abstract][Full Text] [Related]
12. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
Garcia PL; Miller AL; Kreitzburg KM; Council LN; Gamblin TL; Christein JD; Heslin MJ; Arnoletti JP; Richardson JH; Chen D; Hanna CA; Cramer SL; Yang ES; Qi J; Bradner JE; Yoon KJ
Oncogene; 2016 Feb; 35(7):833-45. PubMed ID: 25961927
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
15. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
17. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
[TBL] [Abstract][Full Text] [Related]
18. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
Stalnecker CA; Grover KR; Edwards AC; Coleman MF; Yang R; DeLiberty JM; Papke B; Goodwin CM; Pierobon M; Petricoin EF; Gautam P; Wennerberg K; Cox AD; Der CJ; Hursting SD; Bryant KL
Cancer Res; 2022 Feb; 82(4):586-598. PubMed ID: 34921013
[TBL] [Abstract][Full Text] [Related]
20. Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.
Kumar S; Inigo JR; Kumar R; Chaudhary AK; O'Malley J; Balachandar S; Wang J; Attwood K; Yadav N; Hochwald S; Wang X; Chandra D
Cancer Lett; 2018 Jan; 413():82-93. PubMed ID: 29107110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
